Oral Radiation Nuclear Decorporation Agents

口服辐射核修饰剂

• 批准号: 9357476
• 负责人: GITA SHANKAR
• 金额: $ 4.06万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2017-01-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9357476
• 关键词: Advanced Development; Calcium; Chelating Agents; Complex; Contracts; Enhancers; Excision; Investigational New Drug Application; Metabolic Clearance Rate; National Institute of Allergy and Infectious Disease; Nebulizer; Nuclear; Oral; Pentetic Acid; Plasma; Plutonium; Radiation; Radioactive; Radioisotopes; Research Personnel; Staging; Zinc; absorption; diethylenetriaminepentaacetate; mass casualty; uptake

The removal of certain internal radioactive contaminants can be accomplished by administering chelating agents that can preferentially complex with radionuclides in the body and increase their rate of clearance, thereby decreasing radiation exposure. Pentetate (diethylenetriaminepentaacetate) calcium trisodium (Ca-DTPA) and pentetate (diethylenetriaminepentaacetate) zinc trisodium (Zn-DTPA) have been shown to be effective in treating internal contamination with radionuclides such as plutonium, americium, or curium. However, because DTPA must be given intravenously or by nebulizer, it is not useful in a mass casualty situation. This Contract advances the development of oral forms of Ca-DTPA and Zn-DTPA that are more suitable for a mass casualty situation.

某些内部放射性污染物的去除可以通过施用螯合剂来完成，螯合剂可以优先与体内的放射性核素络合并增加其清除率，从而减少辐射暴露。喷酸（二乙烯三胺五乙酸）三钠钙（Ca-DTPA）和喷酸（二乙烯三胺五乙酸）三钠锌（Zn-DTPA）已被证明可有效治疗钚、镅或锔等放射性核素的内部污染。然而，由于 DTPA 必须静脉注射或通过雾化器给药，因此在大规模伤亡情况下没有用处。该合同促进了更适合大规模伤亡情况的口服 Ca-DTPA 和 Zn-DTPA 的开发。